Ondine Biomedical’s Steriwave Joins NHS Supply Chain

Ondine Biomedical, Inc. (GB:OBI) has released an update.

Ondine Biomedical Inc. has announced the availability of its Steriwave nasal photodisinfection system through the NHS Supply Chain, offering a novel antimicrobial treatment to NHS hospitals in England and Wales. Steriwave, a replacement for the traditional antibiotic mupirocin, aims to prevent healthcare-associated infections by destroying infection-causing pathogens in the nose without inducing antimicrobial resistance. Following a successful pilot at Pontefract Hospital and adoption by Mid Yorkshire Teaching NHS Trust, Steriwave is anticipated to improve patient outcomes and potentially save the NHS millions annually.

For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.